Argenx announced the discontinuation of its Phase 3 UNITY study for efgartigimod in Sjögren's disease due to futility, as recommended by the IDMC. This news led to a sharp decline in Argenx's pre-market shares and contributed to a broader negative sentiment across several other stocks mentioned in the filing.
Argenx's decision to discontinue its Phase 3 UNITY study for efgartigimod in Sjögren's disease is a significant negative catalyst for the company. The recommendation by the IDMC for futility indicates that the drug was unlikely to meet its primary endpoints, representing a setback in its pipeline and potential future revenue streams. This directly impacts Argenx's stock, leading to an 8.7% dip in pre-market trading. For traders, this presents a short-term selling opportunity for ARGX and potentially a long-term re-evaluation of its pipeline. The broader market decline, with Dow futures falling, suggests a general risk-off sentiment, which exacerbates the negative impact on other stocks mentioned, especially those in the biotech sector like Immunovant, which also reported negative trial results.